GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone
Women using oral contraceptives should be advised that delayed gastric emptying, particularly with tirzepatide, may reduce contraceptive efficacy
Also, I have found the service to be helpful and friendly the couple times I have had questions
Patients with type 2 diabetes and obesity inherently face elevated baseline pancreatitis risk due to factors such as hypertriglyceridaemia, gallstones, and metabolic syndrome
Understanding the transition from paroxysmal to persistent atrial fibrillation
IGF-1 Modulators Examples : IGF-1 LR3, IGF-1 DES, Mechano Growth Factor (MGF) What they do : Mimic insulin-like growth factor effects on muscle tissue The problem : These compounds affect everything systemically, not just muscle
